/**
 * Greenstone Peptides — Sanity Blog Post Seeder
 * Run: node scripts/seed-blog-posts.mjs
 *
 * Seeds 10 long-form blog posts + 1 author document into Sanity.
 * Safe to re-run — uses createOrReplace via _id.
 */

import { createClient } from '@sanity/client';
import { readFileSync } from 'fs';
import { resolve, dirname } from 'path';
import { fileURLToPath } from 'url';

const __dirname = dirname(fileURLToPath(import.meta.url));

// Parse .env.local manually (no dotenv dependency needed)
const envPath = resolve(__dirname, '../.env.local');
const envFile = readFileSync(envPath, 'utf-8');
for (const line of envFile.split('\n')) {
  const [key, ...rest] = line.split('=');
  if (key && rest.length) process.env[key.trim()] = rest.join('=').trim();
}

const client = createClient({
  projectId: process.env.NEXT_PUBLIC_SANITY_PROJECT_ID,
  dataset: process.env.NEXT_PUBLIC_SANITY_DATASET || 'production',
  token: process.env.SANITY_API_TOKEN,
  apiVersion: process.env.NEXT_PUBLIC_SANITY_API_VERSION || '2024-01-01',
  useCdn: false,
});

// ─── AUTHOR ───────────────────────────────────────────────────────────────────

const author = {
  _id: 'author-greenstone-team',
  _type: 'author',
  name: 'Greenstone Peptides Editorial Team',
  slug: { _type: 'slug', current: 'greenstone-editorial' },
  credentials: 'Editorial Team',
  bio: 'The Greenstone Peptides editorial team researches and writes about peptide science, compounding standards, and the evolving regulatory landscape. All content is educational and does not constitute medical advice.',
};

// ─── HELPERS ──────────────────────────────────────────────────────────────────

const AUTHOR_REF = { _type: 'reference', _ref: 'author-greenstone-team' };

/** Build a Portable Text block. */
const block = (key, style, text) => ({
  _type: 'block',
  _key: key,
  style,
  markDefs: [],
  children: [{ _type: 'span', _key: `${key}s`, text, marks: [] }],
});

const p = (key, text) => block(key, 'normal', text);
const h2 = (key, text) => block(key, 'h2', text);
const h3 = (key, text) => block(key, 'h3', text);
const quote = (key, text) => block(key, 'blockquote', text);

// ─── POSTS ────────────────────────────────────────────────────────────────────

const posts = [
  // ── POST 1 ─────────────────────────────────────────────────────────────────
  {
    _id: 'post-bpc157-guide',
    _type: 'blogPost',
    title: 'What Is BPC-157? The Complete Guide',
    slug: { _type: 'slug', current: 'what-is-bpc-157-complete-guide' },
    author: AUTHOR_REF,
    publishedAt: '2026-03-12T09:00:00Z',
    excerpt:
      'BPC-157 is a 15-amino-acid peptide fragment derived from a protein found in gastric juice. It has become one of the most discussed recovery peptides in clinical and performance medicine.',
    readingTime: 9,
    featured: true,
    tags: ['recovery', 'peptides', 'BPC-157'],
    seoTitle: 'BPC-157 Complete Guide: Mechanism, Uses, and Clinical Evidence',
    seoDescription:
      'A clinical guide to BPC-157: what it is, how it works via VEGFR2/Akt-eNOS angiogenesis, primary therapeutic uses, and why USA-compounded sourcing matters.',
    body: [
      p('b1',
        'BPC-157, short for Body Protection Compound 157, is a synthetic pentadecapeptide — a chain of fifteen amino acids — derived from a naturally occurring protective protein found in human gastric juice. Over the last two decades it has moved from obscure Croatian research labs to the center of a growing conversation among sports medicine physicians, orthopedic specialists, and longevity clinics. This guide covers what BPC-157 actually is, the mechanisms that drive its healing effects, the documented primary uses, and the questions patients should be asking before any compounded peptide enters their body.'),
      h2('b2', 'What BPC-157 Actually Is'),
      p('b3',
        'BPC-157 is a fragment of a larger protein called Body Protection Compound, which was isolated from human gastric juice in the early 1990s. Researchers observed that the parent protein appeared to protect the gastrointestinal lining from a range of insults, including alcohol, NSAIDs, and stress ulceration. By isolating the active fifteen-amino-acid sequence, they produced a stable, synthesizable peptide that retained the parent protein&rsquo;s cytoprotective and regenerative properties. Unlike many peptides, BPC-157 is remarkably stable in human gastric juice, which has prompted research into both oral and injectable forms.'),
      h2('b4', 'How BPC-157 Works: The VEGFR2/Akt-eNOS Axis'),
      p('b5',
        'The most well-characterized mechanism of BPC-157 involves angiogenesis — the formation of new blood vessels. Peer-reviewed research has shown that BPC-157 upregulates vascular endothelial growth factor receptor 2, commonly abbreviated as VEGFR2. Activation of this receptor triggers a downstream signaling cascade through the Akt and endothelial nitric oxide synthase (eNOS) pathway. The practical result is increased microvascular blood flow to injured tissue, improved oxygen and nutrient delivery, and accelerated recruitment of the cellular machinery responsible for tissue repair.'),
      p('b6',
        'Beyond angiogenesis, BPC-157 appears to modulate growth hormone receptor expression in fibroblasts and tenocytes, which may explain its observed effects on tendon and ligament healing. It also interacts with the nitric oxide system, the dopaminergic system, and several inflammatory pathways, which is why the published research spans such a wide range of conditions.'),
      h2('b7', 'Primary Therapeutic Uses'),
      h3('b8', 'Tendon, Ligament, and Muscle Injury'),
      p('b9',
        'The majority of published BPC-157 research focuses on musculoskeletal repair. Animal studies have demonstrated accelerated healing of transected Achilles tendons, medial collateral ligaments, and injured quadriceps muscle. The mechanism is attributed to both the VEGFR2-driven angiogenesis described above and the direct upregulation of growth hormone receptors in tendon cells. Clinicians working with athletes and chronic-injury patients have adopted BPC-157 as a supportive therapy alongside conventional physical rehabilitation.'),
      h3('b10', 'Gastrointestinal Repair'),
      p('b11',
        'Given its origin in gastric juice, it is unsurprising that BPC-157 shows potent gastroprotective effects. Research documents its ability to accelerate healing of gastric and duodenal ulcers, reduce NSAID-induced GI damage, and support repair of esophageal and colonic tissue in animal models of inflammatory bowel disease. This is one of the few peptides with meaningful data supporting oral administration, because it survives gastric acid and appears to act locally on GI tissue.'),
      h3('b12', 'Neuroprotection and Systemic Effects'),
      p('b13',
        'Animal studies have also shown neuroprotective effects in models of traumatic brain injury and spinal cord damage, though human data in this area remains limited. BPC-157 is best thought of as a supportive therapy — it does not replace surgical repair, structured rehabilitation, or conventional medical management. It may, however, shorten the timeline and improve the quality of healing.'),
      h2('b14', 'Administration, Dosing, and Storage'),
      p('b15',
        'Most USA-compounded BPC-157 is dispensed as a lyophilized powder that is reconstituted with bacteriostatic water before subcutaneous or intramuscular injection. Protocols vary by indication and should always be discussed with a qualified healthcare professional. Once reconstituted, BPC-157 should be refrigerated and used within the stability window documented on the pharmacy&rsquo;s beyond-use date. Greenstone Peptides ships cold-chain to preserve the integrity of every compound.'),
      h2('b16', 'Why USA-Compounded BPC-157 Matters'),
      p('b17',
        'BPC-157 is one of the most commonly counterfeited peptides on the research market. Independent testing of samples purchased from unregulated online sellers has repeatedly shown purity levels ranging from nearly zero to the labeled concentration, with contamination from bacterial endotoxins, heavy metals, and unidentified synthesis byproducts. Injecting these into the body is a meaningful medical risk. Every BPC-157 vial dispensed through Greenstone Peptides is compounded inside a USP 797 compliant pharmacy, tested by an accredited analytical lab, and shipped with a batch-specific Certificate of Analysis.'),
      h2('b18', 'The Bottom Line'),
      p('b19',
        'BPC-157 is one of the more well-researched recovery peptides available today, with a plausible mechanism of action, decades of animal data, and a growing body of clinical experience. It is not a miracle drug. It is a tool — one that works best when sourced from a verified USA compounding pharmacy and used alongside a real rehabilitation plan. If you are considering BPC-157, the first question to ask is not about dosing. It is about where the vial came from.'),
      quote('b20',
        'The difference between a peptide that heals and a peptide that harms is the pharmacy that made it.'),
    ],
    relatedProductSlug: 'bpc-157-5mg',
  },

  // ── POST 2 ─────────────────────────────────────────────────────────────────
  {
    _id: 'post-semaglutide-vs-tirzepatide',
    _type: 'blogPost',
    title: 'Semaglutide vs. Tirzepatide: Which GLP-1 Is Right for You?',
    slug: { _type: 'slug', current: 'semaglutide-vs-tirzepatide' },
    author: AUTHOR_REF,
    publishedAt: '2026-03-17T09:00:00Z',
    excerpt:
      'Semaglutide and tirzepatide are both incretin-based therapies used for weight management and type 2 diabetes, but they work on different receptors and produce meaningfully different clinical results.',
    readingTime: 10,
    featured: true,
    tags: ['weight-loss', 'GLP-1', 'semaglutide', 'tirzepatide'],
    seoTitle: 'Semaglutide vs Tirzepatide: Mechanism, Results, and Candidacy',
    seoDescription:
      'Clinical comparison of semaglutide and tirzepatide — single vs dual incretin action, trial results, side effects, and how to choose between them.',
    body: [
      p('b1',
        'Semaglutide and tirzepatide are the two most widely prescribed injectable peptide therapies for weight management and type 2 diabetes in the United States. They are often discussed together, as if they were interchangeable, but the pharmacology and clinical outcomes are meaningfully different. Choosing between them is a clinical decision that depends on the patient&rsquo;s metabolic profile, tolerance to side effects, cost considerations, and the supervising provider&rsquo;s judgment. This article walks through the science in plain language so patients can have a more informed conversation with their prescriber.'),
      h2('b2', 'The Core Mechanism: Incretin Mimicry'),
      p('b3',
        'Both drugs belong to a family of peptides that mimic incretin hormones — gut-derived molecules the body naturally releases after eating. Incretins signal the pancreas to produce insulin, suppress glucagon, slow gastric emptying, and communicate satiety to the brain. The practical effect is reduced appetite, improved glucose control, and meaningful weight loss when combined with lifestyle change.'),
      h2('b4', 'Semaglutide: A Single-Receptor Agonist'),
      p('b5',
        'Semaglutide is a GLP-1 receptor agonist. It binds to and activates one receptor: the glucagon-like peptide-1 receptor. By acting on GLP-1 alone, it produces the classic incretin effects — appetite suppression, delayed gastric emptying, improved insulin response, and reduced caloric intake. In the STEP clinical trial program, participants on semaglutide achieved average weight loss of approximately 10 to 15 percent of body weight over 68 weeks, depending on the dose and trial arm.'),
      h2('b6', 'Tirzepatide: A Dual GIP/GLP-1 Agonist'),
      p('b7',
        'Tirzepatide activates two receptors: GLP-1 and glucose-dependent insulinotropic polypeptide, abbreviated GIP. GIP is a second incretin hormone that plays a complementary role in insulin secretion and lipid handling. By engaging both receptors simultaneously, tirzepatide produces more pronounced metabolic effects. In the SURMOUNT clinical trial program, participants on tirzepatide achieved average weight loss of approximately 20 to 23 percent of body weight — a meaningfully larger response than semaglutide in head-to-head comparisons.'),
      h2('b8', 'Clinical Trial Results Side by Side'),
      p('b9',
        'The SURMOUNT-5 trial was the first direct head-to-head comparison of tirzepatide and semaglutide for weight loss in patients without diabetes. Tirzepatide produced superior weight reduction across every timepoint measured. That does not mean tirzepatide is the correct choice for every patient — superior average results in a clinical trial do not guarantee superior results for a specific individual — but it does establish that the two drugs are not equivalent.'),
      h2('b10', 'Side Effect Profiles'),
      p('b11',
        'Both drugs share a similar side effect profile dominated by gastrointestinal symptoms: nausea, vomiting, diarrhea, and constipation. These effects are typically dose-dependent, most pronounced during titration, and diminish as the body adapts. Tirzepatide may have a slightly higher incidence of early GI symptoms at equivalent titration stages, though this varies between patients. More serious adverse events — pancreatitis, gallbladder disease, and rare thyroid concerns — are warnings associated with the entire GLP-1 class and should be discussed with a prescribing clinician.'),
      h2('b12', 'Who Is the Right Candidate for Each'),
      p('b13',
        'Tirzepatide tends to be considered first for patients with higher BMI, more significant metabolic dysfunction, or a history of inadequate response to single-receptor GLP-1 therapy. Semaglutide is often appropriate for patients with less aggressive weight-loss goals, those who respond well to single-receptor therapy, or those who cannot tolerate the dual-agonist side effect profile. Cost, availability, and insurance coverage also influence the decision.'),
      h2('b14', 'Compounded vs. Brand-Name'),
      p('b15',
        'Brand-name semaglutide (sold as Wegovy and Ozempic) and brand-name tirzepatide (sold as Zepbound and Mounjaro) remain the gold standard in terms of regulatory pathway and peer-reviewed clinical evidence. Compounded versions are dispensed by licensed compounding pharmacies when medically appropriate and legally permissible. The safety of a compounded GLP-1 depends entirely on the pharmacy that prepared it — USP 797 sterile compounding, batch testing, and traceable sourcing are non-negotiable. Unregulated "research" versions sold online are neither compounded nor tested, and should not be confused with pharmacy-dispensed compounds.'),
      h2('b16', 'The Bottom Line'),
      p('b17',
        'Semaglutide and tirzepatide are both effective, evidence-backed tools for metabolic health. Tirzepatide produces larger average weight-loss outcomes, while semaglutide has a longer post-marketing safety record. Neither replaces diet, exercise, sleep, or the underlying work of behavior change. The right choice is the one made in conversation with a qualified prescriber, with honest consideration of goals, tolerability, and sourcing.'),
    ],
  },

  // ── POST 3 ─────────────────────────────────────────────────────────────────
  {
    _id: 'post-counterfeit-peptides',
    _type: 'blogPost',
    title: 'Why Your Peptides Might Be Counterfeit: The Overseas Quality Crisis',
    slug: { _type: 'slug', current: 'counterfeit-peptides-quality-crisis' },
    author: AUTHOR_REF,
    publishedAt: '2026-03-21T09:00:00Z',
    excerpt:
      'Independent testing has repeatedly shown that peptides sold online vary wildly in purity, potency, and identity. The chemistry is unregulated and the risks are real.',
    readingTime: 11,
    featured: true,
    tags: ['quality', 'safety', 'USA-synthesized'],
    seoTitle: 'The Overseas Peptide Quality Crisis: What Buyers Need to Know',
    seoDescription:
      'Independent lab testing reveals purity failures, heavy metal contamination, and fabricated certificates in online peptides. Here is what legitimate sourcing looks like.',
    body: [
      p('b1',
        'There is a reason peptides sold on obscure research websites cost a fraction of what pharmacy-compounded peptides cost. It is not cleverness, scale, or disruption. It is that the material is largely unregulated, untested, and in a meaningful percentage of cases, not what the label claims. This article walks through the documented quality failures, the regulatory shift that happened in early 2026, and what a legitimate sourcing chain actually looks like.'),
      h2('b2', 'Where Online Peptides Actually Come From'),
      p('b3',
        'Industry analyses consistently estimate that between seventy and ninety percent of peptides sold through online research chemical sellers originate from bulk synthesis facilities in China. These are industrial chemical plants, not pharmacies. They operate with minimal regulatory oversight, few quality control requirements, and no obligation to verify the identity or purity of what they ship. Material crosses borders, passes through reshippers, and arrives in vials with labels that are, at best, aspirational.'),
      h2('b4', 'The Purity Problem'),
      p('b5',
        'Independent laboratory testing of research-grade peptides purchased from online sellers has documented purity ranging from approximately one percent to one hundred percent of the labeled concentration. In practical terms, this means a vial marketed as containing five milligrams of BPC-157 may contain almost no BPC-157 at all — or may contain five milligrams of an entirely different substance. When the injected material is not what the label says, the patient is not dosing a known peptide. They are running an uncontrolled experiment on themselves.'),
      h2('b6', 'Heavy Metal Contamination'),
      p('b7',
        'Multiple reports have documented contamination of overseas peptide imports with heavy metals, including lead, cadmium, and mercury. These metals are byproducts of unclean synthesis, inadequate purification, and the use of contaminated reagents. Unlike an oral contaminant, which passes through the liver and kidneys before reaching the bloodstream, an injected contaminant bypasses first-pass metabolism entirely. The toxic load goes directly into circulation.'),
      h2('b8', 'The Fake Certificate of Analysis Problem'),
      p('b9',
        'A Certificate of Analysis is supposed to be a document produced by an accredited analytical laboratory, tied to a specific batch, and signed by the analyst who performed the testing. In the overseas peptide market, CoAs are frequently fabricated, recycled across unrelated batches, or produced by labs with no accreditation. A PDF is easy to make. A real, batch-specific, accredited CoA tied to the vial in your hand is a different kind of document entirely.'),
      h2('b10', 'The March 2026 FDA Enforcement Action'),
      p('b11',
        'In March 2026, the FDA issued formal warning letters to several prominent research peptide companies, giving them 15 days to cease the shipment of products marketed as "for research use only" but being sold into the consumer market. The warning letters marked the effective end of the "research use only" loophole — a legal fiction that had allowed peptide sellers to operate in a regulatory gray zone for years by claiming their products were for laboratory use while knowingly selling to individuals. Buyers who relied on these suppliers lost access overnight with no recourse and no way to verify the integrity of anything they had already purchased.'),
      h2('b12', 'What USP 797 Actually Requires'),
      p('b13',
        'USP 797 is the United States Pharmacopeia standard for sterile compounding. It requires that injectable compounds be prepared inside an ISO Class 5 clean room environment, with validated air handling, documented cleaning procedures, and personnel trained in aseptic technique. It mandates sterility testing, bacterial endotoxin testing, and beyond-use dating based on stability data. It requires batch records, quality assurance review, and traceable chain of custody. These are not marketing bullet points. They are federal standards with inspection and enforcement behind them.'),
      h2('b14', 'How to Identify a Legitimate Source'),
      p('b15',
        'A legitimate peptide source is a licensed USA compounding pharmacy that operates under state board of pharmacy oversight. It provides real, batch-specific Certificates of Analysis from accredited analytical labs. It ships under cold-chain where stability requires it. It names the pharmacist in charge and maintains full batch traceability. If a website ships peptides without a pharmacy license and without documented third-party testing, it is not a legitimate source regardless of how professional the website looks.'),
      h2('b16', 'The Bottom Line'),
      p('b17',
        'The overseas peptide market is not a bargain. It is a transfer of risk from the seller to the buyer, disguised as a discount. For peptides injected into the body, the only defensible sourcing model is a licensed USA compounding pharmacy operating under USP 797 standards, with batch-specific testing on every lot and full CoA transparency. Greenstone Peptides was built on that model because we believe it is the only model that belongs in a vial that enters a human being.'),
    ],
  },

  // ── POST 4 ─────────────────────────────────────────────────────────────────
  {
    _id: 'post-usp-797',
    _type: 'blogPost',
    title: 'USP 797: What It Means and Why It Matters for Injectable Peptides',
    slug: { _type: 'slug', current: 'usp-797-explained' },
    author: AUTHOR_REF,
    publishedAt: '2026-03-26T09:00:00Z',
    excerpt:
      'USP 797 is the federal standard that governs sterile compounding of injectable medications in the United States. Understanding it is the fastest way to evaluate any peptide source.',
    readingTime: 9,
    featured: false,
    tags: ['quality', 'compounding', 'USP-797', 'safety'],
    seoTitle: 'USP 797 Explained: Sterile Compounding Standards for Peptides',
    seoDescription:
      'A plain-language explanation of USP 797: clean room requirements, sterility testing, endotoxin testing, and why it matters for every injectable peptide.',
    body: [
      p('b1',
        'If you are injecting anything into your body, the standard that governs how it was prepared is USP 797. Most patients have never heard of it. Most peptide sellers hope it stays that way. This article explains what USP 797 actually requires, why those requirements exist, and how to use them as a filter when evaluating any injectable compound — peptide or otherwise.'),
      h2('b2', 'What USP 797 Is'),
      p('b3',
        'USP stands for United States Pharmacopeia, a scientific nonprofit that sets quality standards for medications in the United States. Chapter 797 of the USP is the standard that governs sterile compounding — the preparation of injectable, ophthalmic, and otherwise sterile medications outside of a manufacturer&rsquo;s facility. It is recognized by the FDA and enforced by state boards of pharmacy. Compliance is mandatory for any pharmacy that prepares sterile compounds in the United States.'),
      h2('b4', 'ISO Class 5 Clean Rooms'),
      p('b5',
        'At the center of USP 797 is the requirement that sterile compounding occur inside an ISO Class 5 environment. ISO Class 5 is an air quality classification that limits the number of particles per cubic meter of air to an extremely low threshold. Achieving this requires high-efficiency particulate air filtration, laminar airflow workstations, and validated environmental monitoring. The practical result is an air environment so clean that bacterial and fungal contamination during compounding becomes statistically improbable.'),
      h2('b6', 'Sterility Testing'),
      p('b7',
        'Sterility testing is performed on finished compounds to confirm that the preparation is free of viable microorganisms. Standard sterility testing protocols incubate samples for 14 days to allow slow-growing organisms to become detectable. A peptide that has passed 14-day sterility testing carries meaningful evidence that it is, in fact, sterile. A peptide that has not been tested at all carries no such evidence.'),
      h2('b8', 'Bacterial Endotoxin Testing'),
      p('b9',
        'Even a sterile preparation can be dangerous if it contains bacterial endotoxins — the toxic components of bacterial cell walls that remain active even after the bacteria themselves are killed. Endotoxins can cause fever, shock, and in severe cases, organ failure when injected. USP 797 requires endotoxin testing for sterile compounds using validated methods such as the Limulus Amebocyte Lysate assay. This is one of the most critical differences between a pharmacy-compounded injectable and an unregulated research peptide.'),
      h2('b10', 'Potency Verification'),
      p('b11',
        'Potency testing confirms that the compound contains the labeled amount of active ingredient — no more, no less. This is typically performed using high-performance liquid chromatography. Without potency verification, there is no way to know whether a vial labeled as containing five milligrams of a peptide actually contains five milligrams, half a milligram, or twenty milligrams. Each of those scenarios produces a meaningfully different clinical response in the patient.'),
      h2('b12', 'Why Non-Compliant Injectables Are Dangerous'),
      p('b13',
        'An injectable compound prepared outside USP 797 standards can fail in three primary ways. It can be contaminated with viable microorganisms, leading to local or systemic infection. It can contain bacterial endotoxins, leading to fever and shock. It can contain the wrong amount of active ingredient, leading to therapeutic failure or toxicity. None of these failure modes are theoretical — all have been documented in cases involving non-compliant sterile compounding.'),
      h2('b14', 'How Greenstone Peptides Compares'),
      p('b15',
        'Greenstone Peptides partners exclusively with licensed compounding pharmacies that maintain full USP 797 compliance. Every sterile compound is prepared inside an ISO Class 5 environment, subjected to 14-day sterility testing, screened for bacterial endotoxins, and verified for potency by an accredited analytical laboratory. Every lot carries a batch-specific Certificate of Analysis tied to the vial in your hand. This is not a premium feature. It is the legal and ethical baseline for anything injected into a human body.'),
      h2('b16', 'The Bottom Line'),
      p('b17',
        'USP 797 exists because injectable medications are uniquely dangerous when prepared poorly. The standard is detailed, enforceable, and non-negotiable for legitimate pharmacies. When evaluating any peptide source, the single most important question is whether the preparation occurs inside a USP 797 compliant environment. If the answer is not a clear yes with documentation to back it up, the answer is effectively no.'),
    ],
  },

  // ── POST 5 ─────────────────────────────────────────────────────────────────
  {
    _id: 'post-nad-plus',
    _type: 'blogPost',
    title: 'NAD+: The Anti-Aging Molecule Your Body Makes Less Of Every Decade',
    slug: { _type: 'slug', current: 'nad-plus-anti-aging-molecule' },
    author: AUTHOR_REF,
    publishedAt: '2026-03-29T09:00:00Z',
    excerpt:
      'Nicotinamide adenine dinucleotide — NAD+ — sits at the center of cellular energy production, DNA repair, and longevity signaling. It also declines by roughly half between young adulthood and middle age.',
    readingTime: 9,
    featured: false,
    tags: ['anti-aging', 'longevity', 'NAD+', 'energy'],
    seoTitle: 'NAD+ Explained: Mechanism, Decline, and Delivery Options',
    seoDescription:
      'A clinical overview of NAD+ — what it does, why it declines with age, and how injectable, nasal, and oral precursor approaches actually compare.',
    body: [
      p('b1',
        'NAD+, short for nicotinamide adenine dinucleotide, is not a trendy supplement. It is one of the most fundamental molecules in human biology. It is a coenzyme that every living cell in the body uses to convert food into energy, repair damaged DNA, and regulate the signaling networks that govern aging. It is also a molecule that declines sharply with age — by some estimates, NAD+ levels drop by roughly fifty percent between young adulthood and the age of fifty. That decline is not a rounding error. It has measurable consequences.'),
      h2('b2', 'What NAD+ Actually Does'),
      p('b3',
        'NAD+ serves as an electron carrier in the mitochondrial electron transport chain — the cellular machinery that produces ATP, the body&rsquo;s primary energy currency. Every muscle contraction, every neuron firing, every cellular repair process ultimately depends on ATP, and ATP ultimately depends on NAD+. When NAD+ is abundant, the metabolic engine runs efficiently. When it is depleted, the engine sputters.'),
      h2('b4', 'DNA Repair and the PARP Pathway'),
      p('b5',
        'Beyond energy production, NAD+ is the substrate that poly-ADP ribose polymerase enzymes, commonly abbreviated as PARPs, use to repair damaged DNA. Every cell in the body sustains DNA damage constantly — from ultraviolet light, oxidative stress, metabolic byproducts, and random chemistry. PARP enzymes consume NAD+ to perform repairs. When NAD+ is scarce, repair slows, damage accumulates, and cellular dysfunction compounds.'),
      h2('b6', 'Sirtuins and Longevity Signaling'),
      p('b7',
        'NAD+ is also required for the activity of sirtuins — a family of enzymes that regulate gene expression, inflammatory response, and cellular senescence. Sirtuins have been implicated in many of the pathways associated with healthy aging, including autophagy and mitochondrial biogenesis. Without adequate NAD+, sirtuins cannot function. This is one of the primary mechanistic arguments for maintaining NAD+ levels as the body ages.'),
      h2('b8', 'Why NAD+ Declines'),
      p('b9',
        'The reasons for NAD+ decline are multifactorial. Increased activity of NAD+-consuming enzymes such as CD38 and PARPs, reduced biosynthesis, and changes in cellular redox state all contribute. The decline correlates with many of the hallmarks of aging — fatigue, cognitive slowing, metabolic inflexibility, and reduced exercise tolerance — though correlation is not causation and the full picture remains an active area of research.'),
      h2('b10', 'Delivery Methods: Injectable, Nasal, and Oral Precursors'),
      p('b11',
        'NAD+ can be raised through several delivery routes, and they are not equivalent. Injectable NAD+ bypasses the gut entirely and produces the highest peak serum levels, but requires prescription access, sterile compounding, and a willingness to inject. Intranasal delivery offers reasonable bioavailability with less inconvenience. Oral precursors — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — are metabolized into NAD+ inside the body, but absorption, first-pass metabolism, and conversion efficiency vary considerably between individuals.'),
      h2('b12', 'Who Benefits Most'),
      p('b13',
        'Clinical experience with NAD+ therapy suggests the most pronounced benefits accrue to patients with measurable metabolic dysfunction, chronic fatigue, or accelerated cognitive aging. Younger, healthier patients may notice subtler effects. As with any therapy, the decision to pursue NAD+ should involve a qualified clinician who can evaluate the patient&rsquo;s full metabolic picture.'),
      h2('b14', 'Sourcing Considerations'),
      p('b15',
        'Injectable NAD+ is one of the more difficult compounds to prepare correctly. It is unstable in solution, sensitive to light and temperature, and requires careful formulation to maintain potency through the beyond-use date. A legitimate source is a licensed compounding pharmacy operating under USP 797, with validated stability data and cold-chain distribution. Unregulated online NAD+ is not an acceptable substitute.'),
      h2('b16', 'The Bottom Line'),
      p('b17',
        'NAD+ is real biology, not marketing. Its decline with age is well-documented, its role in cellular function is well-characterized, and the case for maintaining it is compelling. The right approach — injection, nasal, or oral precursor — depends on the patient&rsquo;s goals, budget, and tolerance. The non-negotiable is that any injectable NAD+ must come from a USP 797 compliant pharmacy with verified potency. Everything else is negotiable.'),
    ],
  },

  // ── POST 6 ─────────────────────────────────────────────────────────────────
  {
    _id: 'post-tirzepatide-dosing',
    _type: 'blogPost',
    title: 'Tirzepatide Dosing Protocol: A Clinical Overview',
    slug: { _type: 'slug', current: 'tirzepatide-dosing-protocol' },
    author: AUTHOR_REF,
    publishedAt: '2026-04-01T09:00:00Z',
    excerpt:
      'Tirzepatide dosing follows a slow titration protocol designed to maximize tolerability and minimize gastrointestinal side effects. This overview explains the clinical rationale behind each step.',
    readingTime: 10,
    featured: false,
    tags: ['tirzepatide', 'weight-loss', 'GLP-1', 'protocol'],
    seoTitle: 'Tirzepatide Dosing Protocol: Titration, Side Effects, Timeline',
    seoDescription:
      'Clinical overview of tirzepatide titration — 2.5mg to 15mg schedule, why slow titration matters, managing nausea, and plateau strategies. Consult your prescriber.',
    body: [
      p('b1',
        'Tirzepatide is dosed following a carefully structured titration schedule. The goal of the protocol is not to reach the highest dose as quickly as possible. The goal is to let the body adapt to incretin receptor activation in a way that maximizes therapeutic benefit and minimizes the gastrointestinal side effects that drive discontinuation. This article is a clinical overview of how tirzepatide is typically dosed. It is not personal medical advice. Any decision about dosing should be made with the prescribing clinician who knows your medical history.'),
      h2('b2', 'The Standard Titration Schedule'),
      p('b3',
        'Tirzepatide is typically initiated at 2.5 milligrams once weekly for the first four weeks. This starting dose is considered sub-therapeutic for weight loss — it exists specifically to allow the gut and central nervous system to acclimate to dual-receptor activation before therapeutic dosing begins. After four weeks, the dose is typically increased to 5 milligrams once weekly, which is the first dose with meaningful metabolic effect. Subsequent increases to 7.5, 10, 12.5, and 15 milligrams occur at four-week intervals, as tolerated. Not every patient reaches the 15 milligram dose, and not every patient needs to.'),
      h2('b4', 'Why Slow Titration Matters'),
      p('b5',
        'The GI side effect profile of tirzepatide — nausea, vomiting, diarrhea, and delayed gastric emptying — is dose-dependent. Starting at a therapeutic dose produces a substantially higher incidence of early discontinuation than starting at a sub-therapeutic dose and titrating upward. Slow titration gives the body time to adapt. The receptors downregulate slightly, the central nausea signals attenuate, and the patient develops tolerance to the gastrointestinal effects without losing the therapeutic benefit on appetite and glucose control.'),
      h2('b6', 'Injectable vs. Oral Disintegrating Tablet'),
      p('b7',
        'Most tirzepatide protocols use subcutaneous injection, which delivers consistent serum levels and is well-characterized in the SURMOUNT clinical trial program. Oral disintegrating tablet formulations are offered by some compounding pharmacies as an alternative for patients who cannot tolerate injections. The pharmacokinetic profile of sublingual tirzepatide differs from injection, and clinicians using ODT formulations should base dosing decisions on manufacturer stability data and the patient&rsquo;s clinical response.'),
      h2('b8', 'What to Expect Weeks One Through Twelve'),
      p('b9',
        'During the first four weeks on 2.5 milligrams, most patients notice modest appetite suppression and some early satiety without dramatic side effects or weight change. Weeks five through eight on 5 milligrams typically produce the first measurable weight loss, along with the most pronounced wave of GI side effects as the body adapts to therapeutic dosing. Weeks nine through twelve are often a period of steady, predictable weight loss as the body settles into the new metabolic state.'),
      h2('b10', 'Managing Nausea'),
      p('b11',
        'Nausea is the most common and most disruptive side effect of tirzepatide. Management strategies that reduce its severity include eating smaller meals, avoiding high-fat foods, staying well hydrated, and eating slowly enough to register satiety before overfilling the stomach. Some clinicians prescribe antiemetic medications for the first few weeks of each dose increase. Severe or persistent nausea should always prompt a conversation with the prescriber — it may indicate the need to hold the current dose rather than escalate.'),
      h2('b12', 'Plateau Strategies'),
      p('b13',
        'Weight loss on tirzepatide is not linear. Most patients experience periods of rapid loss followed by plateaus of days or weeks. Plateaus are not evidence that the drug has stopped working — they reflect metabolic adaptation, shifts in water balance, and the normal rhythm of fat loss. Clinically, a true plateau lasting several weeks at a stable dose may prompt evaluation of caloric intake, protein adequacy, resistance training, sleep quality, and whether a dose increase is appropriate. Increasing the dose purely to force progress is not always the right answer.'),
      h2('b14', 'When to Stop'),
      p('b15',
        'Tirzepatide is typically continued until the patient reaches a goal that has been defined with the prescribing clinician, then tapered according to a plan that accounts for weight maintenance and metabolic rebound. Abrupt discontinuation can be associated with rapid appetite return and weight regain. The long-term use of GLP-1 therapies is still an evolving area, and decisions about duration should be made in ongoing collaboration with the prescriber.'),
      h2('b16', 'The Bottom Line'),
      p('b17',
        'Tirzepatide dosing is a clinical protocol, not a guess. The titration schedule exists for a reason, the side effects are manageable with the right strategies, and the outcomes are meaningfully better when the patient stays in contact with a qualified prescriber. The best dose is the lowest dose that achieves the clinical goal — not the highest dose the patient can tolerate. Always consult your prescriber before making any change to your dosing plan.'),
    ],
  },

  // ── POST 7 ─────────────────────────────────────────────────────────────────
  {
    _id: 'post-fda-2026-crackdown',
    _type: 'blogPost',
    title: "The Research Peptide Crackdown: What the FDA's 2026 Enforcement Means for You",
    slug: { _type: 'slug', current: 'fda-2026-peptide-crackdown' },
    author: AUTHOR_REF,
    publishedAt: '2026-04-04T09:00:00Z',
    excerpt:
      'The FDA issued warning letters to research peptide companies in March 2026, effectively ending the "research use only" loophole. Here is what changed and what it means for buyers.',
    readingTime: 10,
    featured: false,
    tags: ['FDA', 'regulation', 'compliance', 'safety'],
    seoTitle: 'FDA 2026 Peptide Crackdown: What It Means for Buyers',
    seoDescription:
      'The FDA ended the research peptide loophole in March 2026. History, enforcement details, and why licensed compounding pharmacies are now the only long-term option.',
    body: [
      p('b1',
        'In March 2026, the United States Food and Drug Administration issued a series of formal warning letters to prominent research peptide companies, giving them fifteen days to cease the shipment of products that were being marketed as "for research use only" but sold into the consumer market. The action marked the effective end of a regulatory workaround that had operated for years, and it fundamentally changed the landscape for anyone relying on unregulated peptide sources. This article explains how the loophole worked, how it ended, and what the change means for people currently buying peptides online.'),
      h2('b2', 'The History of the "Research Use Only" Loophole'),
      p('b3',
        'For most of the last decade, a significant portion of the peptide market in the United States operated under a legal fiction. Companies sold peptides with labels stating the products were for "research use only" and not intended for human consumption. This language was intended to shield sellers from the regulatory requirements that apply to medications — no prescription needed, no pharmacy license required, no sterility testing, no potency verification. Everyone involved understood that the products were being purchased and injected by individual consumers, but the "research use only" label created enough ambiguity to let the industry persist.'),
      h2('b4', 'The September 2023 Category 2 Ban'),
      p('b5',
        'The first major regulatory tightening occurred in September 2023, when the FDA moved several peptides, including BPC-157 and CJC-1295, to Category 2 of its bulk drug substances list. Category 2 designation meant these peptides could no longer be compounded by licensed pharmacies for in-office dispensing through standard pathways. The intent was to limit access to peptides with insufficient safety data in the human regulatory record. The practical effect was to push additional demand toward the unregulated "research" market — until that market itself came under pressure in 2026.'),
      h2('b6', 'The March 2026 Warning Letters'),
      p('b7',
        'In March 2026, the FDA issued warning letters to research peptide companies, including Prime Sciences and Gram Peptides. The letters specifically called out the practice of selling research peptides to individual consumers while claiming they were for laboratory use. Each letter carried a fifteen-day compliance window. Noncompliance would trigger further enforcement, including product seizure, injunctions, and potential criminal referral. Several targeted companies ceased shipments immediately. Others attempted to restructure their business models and were unable to produce compliant alternatives.'),
      h2('b8', 'What Happens to Buyers When Suppliers Shut Down'),
      p('b9',
        'Buyers who relied on shuttered suppliers faced several immediate problems. Material already shipped was in their hands but without recourse if problems emerged. Active protocols were interrupted mid-course, with no comparable source to step into. The online forums that had built up around these products scrambled to identify replacements, most of which were lower-tier suppliers with even less quality control. Some buyers, unable to find alternatives, attempted to source directly from Chinese manufacturers — inheriting all of the purity and contamination risks discussed elsewhere in this blog.'),
      h2('b10', 'Why Compounding Pharmacies Are Now the Only Safe Long-Term Option'),
      p('b11',
        'The 2026 enforcement action made something that was already true legally and clinically much more practically obvious: the only stable long-term source for injectable peptides is a licensed USA compounding pharmacy operating under full USP 797 standards. A pharmacy pathway is not a workaround. It is the actual regulatory structure the FDA recognizes. It involves a licensed pharmacist compounding to order, third-party batch testing, state board oversight, and documentation at every step of the process. It cannot be shut down by a fifteen-day warning letter because it is not operating in a gray zone.'),
      h2('b12', 'The Proposed Reclassification Under RFK Jr.'),
      p('b13',
        'As of the time of writing, there is an ongoing policy conversation around potentially reclassifying certain peptides to restore compounding pathways that were restricted under the 2023 Category 2 decision. Department of Health and Human Services leadership under Secretary Robert F. Kennedy Jr. has publicly discussed this possibility. No reclassification has been enacted, and any future change would move through the formal regulatory process. Patients should not base sourcing decisions on hypothetical future rule changes.'),
      h2('b14', 'What This Means Practically'),
      p('b15',
        'If you are currently using peptides from a research supplier, the practical guidance is straightforward. Evaluate whether the peptide you are using is clinically appropriate for your situation. Have that conversation with a qualified clinician. If it is appropriate, transition to a sourcing pathway that operates through a licensed compounding pharmacy with full USP 797 compliance and batch-specific testing. If it is not appropriate, stop using it. The research peptide era is effectively over for anyone who wants a source that will still exist in six months.'),
      h2('b16', 'The Bottom Line'),
      p('b17',
        'The FDA&rsquo;s March 2026 enforcement action was not a sudden shift. It was the enforcement of rules that had always existed, finally applied to a segment of the market that had been operating outside them. The legitimate pharmacy model — prescription, compounding, testing, documentation — is not new. It is the standard that has always applied to injectable medications in the United States. Greenstone Peptides was built entirely within that standard because it is the only model with any long-term future.'),
    ],
  },

  // ── POST 8 ─────────────────────────────────────────────────────────────────
  {
    _id: 'post-sermorelin-vs-hgh',
    _type: 'blogPost',
    title: 'Sermorelin vs. HGH Replacement: Why Natural Stimulation Wins',
    slug: { _type: 'slug', current: 'sermorelin-vs-hgh' },
    author: AUTHOR_REF,
    publishedAt: '2026-04-06T09:00:00Z',
    excerpt:
      'Sermorelin is a growth hormone releasing hormone analogue that stimulates the body to produce its own pulsatile GH, rather than replacing it with synthetic injections. The distinction matters.',
    readingTime: 9,
    featured: false,
    tags: ['growth-hormone', 'sermorelin', 'anti-aging', 'longevity'],
    seoTitle: 'Sermorelin vs HGH: Pulsatile Release and Long-Term Safety',
    seoDescription:
      'Why sermorelin — a GHRH analogue that stimulates natural pulsatile GH release — is preferred over exogenous HGH for long-term growth hormone optimization.',
    body: [
      p('b1',
        'Sermorelin and human growth hormone replacement are two fundamentally different approaches to the same clinical problem: the age-related decline in growth hormone output. They are often discussed as if they were interchangeable options, but the pharmacology and the long-term safety profile differ significantly. For most patients considering growth hormone optimization outside of a diagnosed deficiency state, sermorelin is the more defensible choice. This article explains why.'),
      h2('b2', 'What Sermorelin Actually Is'),
      p('b3',
        'Sermorelin is a synthetic analogue of growth hormone releasing hormone, the hypothalamic peptide that signals the pituitary gland to release growth hormone. Functionally, sermorelin does not add growth hormone to the body. It tells the body&rsquo;s own pituitary to release the growth hormone it is already capable of producing. This is a meaningful mechanistic distinction that drives every subsequent difference between sermorelin and exogenous HGH.'),
      h2('b4', 'How Natural Pulsatile Release Works'),
      p('b5',
        'Growth hormone is not secreted continuously. The pituitary releases it in discrete pulses, with the largest pulses occurring during deep sleep. This pulsatile pattern is not incidental. The body&rsquo;s receptors respond differently to pulsed hormone exposure than to continuous exposure, and feedback loops operate on the assumption of a pulsatile rhythm. When growth hormone is replaced with synthetic HGH injections, the serum levels do not follow this natural rhythm — they spike and decay based on injection timing and pharmacokinetics, not physiology.'),
      h2('b6', 'Why Pulsatile Matters'),
      p('b7',
        'Continuous or non-physiologic GH exposure has been associated with receptor desensitization and disruption of the normal feedback regulation of the somatotropic axis. The body senses that growth hormone is abundant and downregulates its own production, which becomes a problem when the exogenous source is eventually removed. Sermorelin, by stimulating the endogenous pulsatile release, preserves the natural rhythm and the feedback mechanisms that support long-term system integrity.'),
      h2('b8', 'Documented Benefits'),
      p('b9',
        'Sermorelin therapy has been associated with improvements in lean muscle mass, body composition, sleep quality, skin elasticity, and subjective energy levels in patients with age-related decline in growth hormone output. The benefits are typically more gradual than those seen with direct HGH injection, but they develop in a way that respects the body&rsquo;s regulatory architecture rather than overriding it.'),
      h2('b10', 'Who Is a Candidate'),
      p('b11',
        'Sermorelin is most appropriate for adults with symptomatic age-related decline in growth hormone output who wish to support endogenous hormonal function rather than replace it. Candidates should be evaluated by a qualified clinician with appropriate laboratory testing, including IGF-1 levels, to confirm that intervention is appropriate. It is not a first-line therapy for diagnosed growth hormone deficiency, which may require true HGH replacement under endocrinology supervision.'),
      h2('b12', 'Why It Is Preferred Over Exogenous HGH for Long-Term Use'),
      p('b13',
        'Exogenous HGH has a more dramatic acute effect profile, but it also carries a more concerning long-term risk profile. Continuous non-physiologic exposure to high levels of growth hormone and its downstream mediator IGF-1 has been associated with insulin resistance, carpal tunnel syndrome, fluid retention, and theoretical concerns about accelerated cellular proliferation. Sermorelin sidesteps most of these concerns because the body&rsquo;s own regulatory mechanisms remain engaged. If the pituitary detects that GH levels are high enough, it does not release more. This built-in safety valve does not exist when GH is injected directly.'),
      h2('b14', 'Administration and Sourcing'),
      p('b15',
        'Sermorelin is typically dispensed as a lyophilized powder reconstituted with bacteriostatic water and administered by subcutaneous injection, usually before bed to align with natural GH release patterns. Dosing is individualized and should be supervised by a prescribing clinician with experience in hormonal optimization. As with every injectable compound, sourcing matters. Sermorelin must be prepared in a USP 797 compliant compounding pharmacy, tested for potency and sterility, and shipped cold-chain to preserve stability.'),
      h2('b16', 'The Bottom Line'),
      p('b17',
        'Sermorelin is not a weaker version of HGH. It is a different tool that works with the body rather than around it. For long-term growth hormone optimization in patients without a diagnosed deficiency, working with the body is almost always the more defensible strategy. The results come more slowly, but they come in a way that preserves the regulatory systems that keep the rest of the endocrine architecture intact.'),
    ],
  },

  // ── POST 9 ─────────────────────────────────────────────────────────────────
  {
    _id: 'post-retatrutide',
    _type: 'blogPost',
    title: 'What Is Retatrutide? The Triple Agonist Changing Weight Loss',
    slug: { _type: 'slug', current: 'what-is-retatrutide' },
    author: AUTHOR_REF,
    publishedAt: '2026-04-09T09:00:00Z',
    excerpt:
      'Retatrutide is an investigational triple agonist that activates GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 trial results have been striking, with average weight loss approaching 29 percent.',
    readingTime: 9,
    featured: false,
    tags: ['retatrutide', 'weight-loss', 'GLP-1'],
    seoTitle: 'Retatrutide: Triple Agonist Mechanism and Phase 3 Results',
    seoDescription:
      'Retatrutide activates GLP-1, GIP, and glucagon receptors. Phase 3 TRIUMPH trial results, comparison to semaglutide and tirzepatide, and current status.',
    body: [
      p('b1',
        'Retatrutide represents what may be the next generation of incretin-based metabolic therapy. Where semaglutide acts on one receptor and tirzepatide acts on two, retatrutide activates three receptors simultaneously — GLP-1, GIP, and glucagon. The clinical trial results have been striking enough to prompt serious discussion about what happens to the weight loss pharmaceutical landscape when retatrutide eventually reaches the market. This article covers the mechanism, the published trial results, the comparison to currently available options, and what patients should understand about the regulatory timeline.'),
      h2('b2', 'The Triple Agonist Mechanism'),
      p('b3',
        'Retatrutide is engineered to bind and activate three distinct receptors. The first two — glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide — are the same receptors engaged by tirzepatide. The third is the glucagon receptor, which is not engaged by semaglutide or tirzepatide. Adding glucagon receptor activation to incretin action produces a meaningfully different metabolic effect profile.'),
      h2('b4', 'Why Glucagon Activation Changes Things'),
      p('b5',
        'Glucagon is typically thought of as a counter-regulatory hormone that raises blood sugar. However, glucagon also has significant effects on energy expenditure and hepatic lipid metabolism. Pharmacologic activation of the glucagon receptor in the presence of incretin action appears to increase basal metabolic rate, enhance lipolysis, and improve hepatic fat handling. The net effect is additional weight loss beyond what incretin activation alone can produce, without the hyperglycemic effects that would be expected from glucagon in isolation.'),
      h2('b6', 'Phase 3 TRIUMPH Trial Results'),
      p('b7',
        'The TRIUMPH clinical trial program has reported Phase 3 results demonstrating average weight loss of approximately 28.7 percent of baseline body weight in participants receiving the highest retatrutide dose over the full trial duration. For context, semaglutide in comparable trials produced average weight loss in the 10 to 15 percent range, and tirzepatide produced average weight loss in the 20 to 23 percent range. Retatrutide&rsquo;s results represent a meaningful additional step rather than a marginal improvement.'),
      h2('b8', 'Comparison to Semaglutide and Tirzepatide'),
      p('b9',
        'A simple mental model is that each successive agonist adds an additional metabolic lever. Semaglutide pulls the GLP-1 lever. Tirzepatide pulls GLP-1 and GIP. Retatrutide pulls GLP-1, GIP, and glucagon. Each additional receptor adds therapeutic effect but also adds complexity to the side effect profile and the clinical decision-making that surrounds prescribing. Higher efficacy does not automatically mean better fit for every patient.'),
      h2('b10', 'Side Effects and Safety Profile'),
      p('b11',
        'Retatrutide shares the gastrointestinal side effect profile of the incretin class — nausea, vomiting, diarrhea, and early satiety. Trial data suggests the intensity scales roughly with the magnitude of metabolic effect, meaning retatrutide produces more pronounced GI effects during titration than tirzepatide or semaglutide. The long-term safety profile is still accumulating. As with any new-class therapy, the post-marketing surveillance period that follows approval will reveal effects that may not have been apparent in the controlled trial setting.'),
      h2('b12', 'Timeline to FDA Approval'),
      p('b13',
        'As of the time of writing, retatrutide remains an investigational compound. The expected timeline for full FDA approval is 2027, assuming the Phase 3 program completes on schedule and the application moves through the FDA review process without significant delays. No compounded version of retatrutide is available through legitimate pharmacy pathways, and any "retatrutide" being sold today through research channels is unregulated material of unknown identity and purity.'),
      h2('b14', 'Why This Matters for Current Decisions'),
      p('b15',
        'Patients sometimes ask whether they should delay starting tirzepatide or semaglutide and wait for retatrutide to become available. In most cases, the answer is no. Tirzepatide and semaglutide are approved, proven, and available now. The correct time to start treatment is when treatment is clinically indicated, not at some hypothetical future moment. When retatrutide is approved and available through legitimate compounding pathways, patients can evaluate whether transitioning is appropriate for their situation at that point.'),
      h2('b16', 'The Bottom Line'),
      p('b17',
        'Retatrutide represents a genuine advance in the science of metabolic therapy. The triple agonist mechanism is novel, the Phase 3 results are impressive, and the drug will likely become an important clinical option once it is approved and available through legitimate channels. For now, it is a development to follow, not a product to seek out through unregulated sources. Patients who are ready to start treatment have excellent options in semaglutide and tirzepatide today, both available through Greenstone Peptides&rsquo; licensed compounding partners.'),
    ],
  },

  // ── POST 10 ────────────────────────────────────────────────────────────────
  {
    _id: 'post-ghk-cu',
    _type: 'blogPost',
    title: 'GHK-Cu: The Copper Peptide Rewriting Anti-Aging Science',
    slug: { _type: 'slug', current: 'ghk-cu-copper-peptide' },
    author: AUTHOR_REF,
    publishedAt: '2026-04-11T09:00:00Z',
    excerpt:
      'GHK-Cu is a naturally occurring copper-binding tripeptide that modulates over four thousand genes, supports collagen and elastin synthesis, and behaves unlike any other anti-aging molecule.',
    readingTime: 9,
    featured: false,
    tags: ['anti-aging', 'GHK-Cu', 'skin', 'longevity'],
    seoTitle: 'GHK-Cu Copper Peptide: Mechanism, Uses, and Delivery Methods',
    seoDescription:
      'A clinical look at GHK-Cu — its 4,000-gene modulation, collagen synthesis, hair growth research, wound healing, and injectable vs topical delivery.',
    body: [
      p('b1',
        'GHK-Cu, or glycyl-L-histidyl-L-lysine copper complex, is one of the more unusual molecules in the longevity and skin health conversation. It is a naturally occurring tripeptide — three amino acids bound to a copper ion — that the human body produces in decreasing quantities with age. Research into GHK-Cu has documented effects that span wound healing, skin remodeling, hair follicle stimulation, and gene expression modulation across thousands of targets. This article explains what it is, how it works, and why copper peptides occupy a different category than most anti-aging compounds.'),
      h2('b2', 'What GHK-Cu Actually Is'),
      p('b3',
        'The GHK sequence — glycine, histidine, lysine — was first isolated from human plasma in 1973 by researchers who observed that plasma from younger donors could restore certain regenerative capacities in tissue from older donors. The active component was identified as the GHK tripeptide bound to a copper ion. The copper binding is not incidental. It is essential to the molecule&rsquo;s biological activity. GHK-Cu levels in human plasma decline significantly after the third decade of life, which correlates with a range of skin and tissue changes associated with aging.'),
      h2('b4', 'The 4,000-Gene Modulation Effect'),
      p('b5',
        'One of the most striking findings in GHK-Cu research was a gene expression study that examined its effects on the human fibroblast transcriptome. GHK-Cu was shown to modulate the expression of more than four thousand genes — roughly a third of the known human genome expressed in those cells. The modulation was not random. It systematically shifted gene expression toward patterns associated with younger cells: upregulating DNA repair, antioxidant defense, collagen synthesis, and tissue remodeling while downregulating inflammatory and pro-aging pathways.'),
      h2('b6', 'Collagen and Elastin Synthesis'),
      p('b7',
        'GHK-Cu directly stimulates fibroblasts to produce collagen and elastin, the structural proteins that give skin its firmness and elasticity. It also activates metalloproteinases and their inhibitors in a way that supports tissue remodeling — breaking down damaged extracellular matrix and replacing it with new, properly organized structural protein. This dual effect distinguishes GHK-Cu from compounds that simply add collagen without addressing the quality of the underlying matrix.'),
      h2('b8', 'Hair Growth Research'),
      p('b9',
        'Clinical research has also documented GHK-Cu&rsquo;s ability to stimulate hair follicles, extend the anagen growth phase, and increase follicle size. Some studies have shown effects comparable to minoxidil in early hair restoration outcomes. The mechanism is attributed to improved perifollicular microcirculation and direct signaling to hair follicle stem cells.'),
      h2('b10', 'Wound Healing'),
      p('b11',
        'The original research interest in GHK-Cu was its wound healing properties. Studies have shown accelerated healing of cutaneous wounds, improved tensile strength of healed tissue, and reduced scarring. The mechanism combines the collagen synthesis effects described above with pro-angiogenic signaling that improves blood supply to healing tissue.'),
      h2('b12', 'Injectable vs. Topical Delivery'),
      p('b13',
        'GHK-Cu can be delivered topically, by subcutaneous injection, or occasionally intravenously. Topical delivery is the most widely used route and is particularly well-suited to skin-focused outcomes because the molecule acts directly on fibroblasts in the dermis. Subcutaneous injection provides more systemic exposure and is sometimes used in protocols focused on hair restoration or systemic tissue remodeling. The choice of delivery route should be made in consultation with a clinician based on the specific clinical goal.'),
      h2('b14', 'Why Copper Peptides Are Different'),
      p('b15',
        'Most of the anti-aging compounds in widespread use — retinoids, vitamin C derivatives, hydroxy acids — work primarily through mechanisms of exfoliation, antioxidation, or forced cell turnover. GHK-Cu works through a fundamentally different mechanism: it communicates with the cell at the gene expression level, effectively telling fibroblasts and related cells to behave more like their younger counterparts. This is not the same category of intervention. It is a signaling molecule that speaks the cell&rsquo;s own language.'),
      h2('b16', 'Sourcing and Quality'),
      p('b17',
        'Injectable GHK-Cu, like every other compounded peptide, must come from a USP 797 compliant pharmacy with batch-specific testing for potency, sterility, and endotoxins. The copper binding adds additional formulation complexity that makes sourcing quality even more critical — an improperly prepared copper peptide can be either inactive or locally irritating. Greenstone Peptides dispenses GHK-Cu exclusively through licensed pharmacy partners with documented quality controls for every lot.'),
      h2('b18', 'The Bottom Line'),
      p('b19',
        'GHK-Cu is one of the more interesting molecules in the anti-aging conversation because it works through a genuinely novel mechanism, is supported by decades of research, and produces effects that are measurable rather than merely marketed. It is not a replacement for retinol, vitamin C, or sun protection. It is an addition to the toolkit that addresses the aging process at a level most topical compounds cannot reach. As always, the foundation of any meaningful protocol is sourcing — the most elegant mechanism in the world does not matter if the vial in your hand does not contain what the label claims.'),
    ],
  },
  // ── POST 11 ────────────────────────────────────────────────────────────────
  {
    _id: 'post-usa-compounded-cost',
    _type: 'blogPost',
    title: 'Why USA-Compounded Peptides Cost More (And Why It Matters)',
    slug: { _type: 'slug', current: 'why-usa-compounded-peptides-cost-more' },
    author: AUTHOR_REF,
    publishedAt: '2026-04-13T09:00:00Z',
    excerpt:
      'Over 70% of peptides sold online originate from unregulated overseas synthesis facilities. The price difference between those products and USA-compounded peptides reflects something real.',
    readingTime: 6,
    featured: true,
    tags: ['quality', 'USA-compounded', 'peptides', 'safety'],
    seoTitle: 'Why USA-Compounded Peptides Cost More | Greenstone Peptides',
    seoDescription:
      'Over 70% of peptides sold online are synthesized in China. Learn why USA-compounded peptides cost more and why quality matters.',
    body: [
      p('b1',
        'If you have priced peptides online, you have noticed the gap. The same compound — BPC-157, TB-500, Sermorelin — sells for a fraction of the cost from overseas research chemical sellers compared to what a licensed USA compounding pharmacy charges. The temptation to read that price difference as a markup is understandable. It is not. The price difference reflects a genuine difference in what you are buying.'),
      h2('b2', 'Where Most Online Peptides Come From'),
      p('b3',
        'Industry analysis consistently estimates that more than seventy percent of peptides sold through online research chemical markets originate from bulk synthesis facilities in China. These are industrial chemical production operations, not pharmacies, not GMP-certified manufacturers, and not laboratories with meaningful quality control infrastructure. The peptide is synthesized, packaged, labeled, and shipped with minimal regulatory oversight and no obligation to verify what the vial actually contains.'),
      p('b4',
        'The raw cost of producing peptide material in these facilities is low — sometimes genuinely low. But the price savings accrue to the seller, not the buyer. What the buyer pays in cost savings, they pay in risk.'),
      h2('b5', 'The Purity Variance Problem'),
      p('b6',
        'Independent laboratory testing of research-grade peptides purchased from unregulated online sellers has documented purity ranging from roughly one percent to one hundred percent of the labeled concentration. That is not a narrow statistical spread — it is the difference between a vial that contains almost nothing and a vial that contains twenty times the intended dose. Both scenarios are dangerous when the material is injected. Underdosing produces therapeutic failure. Overdosing produces unpredictable physiologic effects. Neither is acceptable.'),
      p('b7',
        'A vial of USA-compounded BPC-157 from a licensed pharmacy operating under USP 797 standards carries potency verification by an accredited analytical laboratory. High-performance liquid chromatography confirms the compound is present at the labeled concentration — no more, no less. That verification does not happen for free.'),
      h2('b8', 'What USP 797 Compliance Actually Costs'),
      p('b9',
        'USP 797 requires compounding to occur inside an ISO Class 5 clean room environment. ISO Class 5 air quality requires high-efficiency particulate filtration, laminar airflow workstations, continuous environmental monitoring, and personnel trained in aseptic technique. The infrastructure costs are significant. Then there are the mandatory testing requirements: 14-day sterility testing, bacterial endotoxin testing, potency verification, and beyond-use dating backed by stability data. Each test is performed by an accredited analytical laboratory, against each batch, before any product leaves the facility.'),
      p('b10',
        'These are not premium add-ons that a pharmacy chooses to include. They are the minimum federal standards for sterile compounding in the United States. They are also why USA-compounded peptides cost what they cost.'),
      h2('b11', 'The Certificate of Analysis: Real vs. Fabricated'),
      p('b12',
        'Many overseas peptide sellers provide a document they call a Certificate of Analysis. The CoA is supposed to be a batch-specific testing report produced by an accredited laboratory and signed by the analyst who performed the work. In practice, overseas CoAs are frequently recycled across batches, fabricated in PDF editors, or sourced from labs with no meaningful accreditation. A PDF is easy to produce. A real, batch-specific CoA tied to a specific lot from an ISO 17025 accredited laboratory is a different document entirely.'),
      p('b13',
        'Every compound dispensed through Greenstone Peptides carries a genuine batch-specific Certificate of Analysis from an accredited third-party laboratory. That traceability is part of what you are paying for.'),
      h2('b14', 'Cold-Chain Distribution'),
      p('b15',
        'Peptides are temperature-sensitive compounds. Many degrade meaningfully when stored above refrigeration temperatures. USA-compounded peptides from licensed pharmacies are shipped cold-chain — packed with ice packs or dry ice, using insulated carriers, with monitoring to ensure the product arrives within the validated temperature range. Overseas peptides are typically shipped at ambient temperature across international logistics chains that may take weeks and may expose the product to conditions that compromise potency before it ever arrives.'),
      h2('b16', 'The Bottom Line'),
      p('b17',
        'USA-compounded peptides cost more because they are something different. The price includes clean room manufacturing, third-party testing, accredited CoA documentation, and cold-chain shipping. The price of overseas peptides does not include any of those things — it is the cost of raw synthesis and a label. The question is not whether you can afford USA-compounded peptides. The question is whether you can afford to inject something into your body when you do not know what it is.'),
    ],
  },

  // ── POST 12 ────────────────────────────────────────────────────────────────
  {
    _id: 'post-beginners-guide-peptide-therapy',
    _type: 'blogPost',
    title: "The Beginner's Guide to Peptide Therapy",
    slug: { _type: 'slug', current: 'beginners-guide-to-peptide-therapy' },
    author: AUTHOR_REF,
    publishedAt: '2026-04-14T09:00:00Z',
    excerpt:
      'Peptide therapy is one of the fastest-growing areas of health optimization. If you are new to it, here is what you need to understand before you start.',
    readingTime: 8,
    featured: false,
    tags: ['peptides', 'beginner', 'guide', 'therapy'],
    seoTitle: "Beginner's Guide to Peptide Therapy | Greenstone Peptides",
    seoDescription:
      'New to peptides? Learn what peptide therapy is, how it works, common categories, and how to get started safely.',
    body: [
      p('b1',
        'Peptide therapy has moved from the margins of sports medicine and longevity clinics into wider conversation, and for good reason. Peptides are precise biological tools — short chains of amino acids that signal the body to do specific things. Understanding what they are, how they work, and what the major categories are used for gives you a foundation to make informed decisions about whether they belong in your health protocol.'),
      h2('b2', 'What Peptides Are'),
      p('b3',
        'Peptides are short chains of amino acids — the same building blocks that make up proteins, but in smaller, more targeted sequences. The human body produces thousands of peptides naturally. They function as hormones, neurotransmitters, growth factors, and signaling molecules. Insulin is a peptide. Growth hormone releasing hormone is a peptide. The gastric protective protein that led to the discovery of BPC-157 is a peptide.'),
      p('b4',
        'Therapeutic peptides are either identical to naturally occurring human peptides or analogues — slightly modified versions designed to improve stability, extend half-life, or target a specific receptor more precisely. The key distinction from small-molecule drugs is that peptides work by communicating with the body&rsquo;s existing systems rather than overriding them. That is both their strength and the reason they tend to have cleaner side-effect profiles than many conventional pharmaceuticals.'),
      h2('b5', 'How Peptide Therapy Works'),
      p('b6',
        'When a peptide is administered — typically by subcutaneous injection, though some are delivered nasally, orally, or topically — it enters circulation and binds to specific receptors on cell surfaces. That binding triggers a cascade of downstream effects inside the cell. Depending on the peptide and the receptor, those effects might include increased collagen synthesis, accelerated tissue repair, modulated inflammatory response, stimulated growth hormone release, or improved insulin sensitivity.'),
      p('b7',
        'The precision of peptide action is one of its defining features. A peptide that activates VEGFR2 receptors drives angiogenesis — new blood vessel formation — in injured tissue without producing the systemic hormonal flooding that broader interventions create. This selectivity is why clinicians use specific peptides for specific goals rather than treating them as interchangeable.'),
      h2('b8', 'Common Categories of Peptide Therapy'),
      h3('b9', 'Recovery and Musculoskeletal Repair'),
      p('b10',
        'The recovery category includes peptides like BPC-157 and TB-500 that accelerate healing of tendons, ligaments, muscles, and GI tissue. These are the peptides most commonly used by athletes and active individuals dealing with chronic injury or post-surgical recovery. BPC-157 works primarily through angiogenesis and growth hormone receptor upregulation in tendon cells. TB-500 works through thymosin beta-4, a protein that regulates actin and promotes cell migration to sites of injury.'),
      h3('b11', 'Weight Loss and Metabolic Health'),
      p('b12',
        'The GLP-1 category — semaglutide, tirzepatide, and in the near future retatrutide — represents the most commercially visible corner of peptide therapy. These incretin-mimicking peptides suppress appetite, improve insulin response, and produce meaningful, sustained weight loss when combined with lifestyle change. They are among the most clinically studied peptides available.'),
      h3('b13', 'Anti-Aging and Longevity'),
      p('b14',
        'Anti-aging peptides include NAD+ (which is technically a coenzyme rather than a peptide but is commonly grouped with them), GHK-Cu, and various growth hormone secretagogues. This category targets the cellular machinery of aging — DNA repair, mitochondrial function, collagen synthesis, and gene expression modulation. Results are typically more gradual than recovery or weight-loss peptides, and the evidence base varies considerably between compounds.'),
      h3('b15', 'Growth Hormone Optimization'),
      p('b16',
        'Growth hormone secretagogues like sermorelin, ipamorelin, and CJC-1295 stimulate the pituitary gland to produce more of the body&rsquo;s own growth hormone. They differ from exogenous HGH in that they work with the body&rsquo;s regulatory architecture rather than replacing it. The result is a more physiologic GH profile, with pulsatile release preserved and the body&rsquo;s own safety mechanisms remaining engaged.'),
      h2('b17', 'Getting Started: Storage and Administration Basics'),
      p('b18',
        'Most injectable peptides are dispensed as lyophilized powders — freeze-dried material in a sealed vial. Before use, they are reconstituted with bacteriostatic water. Once reconstituted, they should be stored refrigerated, away from light, and used within the beyond-use date documented by the compounding pharmacy.'),
      p('b19',
        'Subcutaneous injection — delivered into the fatty tissue just beneath the skin, typically on the abdomen or thigh — is the most common administration route. The needles used are small and the injection is typically well tolerated. Proper injection technique, site rotation, and attention to sterility are important for safety and efficacy.'),
      h2('b20', 'The Foundation: Sourcing Quality'),
      p('b21',
        'The single most important decision in peptide therapy is where the compound comes from. Independent testing has repeatedly documented that peptides sold through unregulated research channels vary wildly in purity, potency, and identity. A vial that is not what the label claims produces unpredictable effects at best and genuine medical risk at worst. USA-compounded peptides from licensed pharmacies operating under USP 797 standards — with documented sterility testing, bacterial endotoxin testing, and potency verification — are the only defensible starting point.'),
      p('b22',
        'Greenstone Peptides sources exclusively through licensed USA compounding pharmacy partners with full USP 797 compliance and batch-specific Certificates of Analysis on every lot. If you are starting peptide therapy, start with verified material.'),
    ],
  },

  // ── POST 13 ────────────────────────────────────────────────────────────────
  {
    _id: 'post-how-to-store-peptides',
    _type: 'blogPost',
    title: 'How to Store Peptides: Temperature, Light, and Shelf Life',
    slug: { _type: 'slug', current: 'how-to-store-peptides' },
    author: AUTHOR_REF,
    publishedAt: '2026-04-15T09:00:00Z',
    excerpt:
      'Improper storage is one of the most common causes of peptide potency loss. Here is what you need to know about temperature, light, reconstitution, and shelf life.',
    readingTime: 5,
    featured: false,
    tags: ['storage', 'peptides', 'safety', 'guide'],
    seoTitle: 'How to Store Peptides Properly | Greenstone Peptides',
    seoDescription:
      'Proper peptide storage is critical for potency. Learn temperature, light, and shelf life requirements for your peptides.',
    body: [
      p('b1',
        'Peptides are sensitive compounds. The same molecular precision that makes them effective biological tools also makes them susceptible to degradation when they are stored or handled incorrectly. Potency loss from improper storage does not look like anything — you cannot see it, smell it, or taste it. The vial looks exactly the same whether the active compound is intact or largely broken down. Understanding storage requirements is not optional for anyone who wants to use peptides effectively.'),
      h2('b2', 'Lyophilized vs. Reconstituted: Two Different States'),
      p('b3',
        'Peptides are dispensed in one of two states: lyophilized (freeze-dried) powder or reconstituted solution. These two states have meaningfully different storage requirements, and the clock on shelf life moves differently for each.'),
      p('b4',
        'Lyophilized peptides — sealed in a vial as a dry powder — are significantly more stable than reconstituted solutions. They can typically be stored refrigerated for months and frozen for longer periods. Reconstituted peptides in solution are far more vulnerable to degradation, particularly from temperature fluctuations, light, and time. The moment you add bacteriostatic water to a lyophilized vial, the countdown on shelf life begins.'),
      h2('b5', 'Temperature Requirements'),
      p('b6',
        'Lyophilized peptides should be stored refrigerated at 2–8°C (35–46°F) for day-to-day use. If you need to store them for an extended period beyond the standard beyond-use date, deep freezing at -20°C or below can extend stability for many compounds. Avoid freeze-thaw cycling — repeated freezing and thawing degrades peptide structure over time.'),
      p('b7',
        'Reconstituted peptides in solution must be refrigerated and should not be frozen. The bacteriostatic water used for reconstitution keeps the solution stable under refrigeration, but freezing the liquid can disrupt the peptide&rsquo;s molecular structure. Room temperature storage of reconstituted peptides accelerates degradation significantly and is not recommended.'),
      h2('b8', 'Light Sensitivity'),
      p('b9',
        'Most peptides are light-sensitive, particularly in reconstituted form. UV light from sunlight and fluorescent lighting degrades peptide bonds over time. This is why compounding pharmacies dispense peptides in amber glass vials and why you should keep vials away from direct light during storage and handling. When drawing a dose, work quickly and return the vial to storage rather than leaving it on a countertop.'),
      h2('b10', 'Reconstitution: Getting It Right'),
      p('b11',
        'Reconstitution should always use bacteriostatic water — sterile water preserved with benzyl alcohol, which prevents microbial growth in the solution after the vial is opened. Regular sterile water is not a substitute for multi-dose vials because it lacks the antimicrobial preservation required for repeated needle entries.'),
      p('b12',
        'When adding bacteriostatic water to a lyophilized peptide, inject the water slowly down the side of the vial rather than directly onto the peptide cake. Swirl gently to dissolve — do not shake vigorously. Agitation can denature the peptide and reduce potency. Let the solution sit if needed until the powder is fully dissolved.'),
      h2('b13', 'Shelf Life and Beyond-Use Dates'),
      p('b14',
        'The beyond-use date on your compounded peptide vial is not an approximation. It is based on stability data validated by the compounding pharmacy and represents the date after which the compound can no longer be guaranteed to meet its labeled potency specification. Using a peptide past its beyond-use date means you are working with unknown potency — which defeats the purpose of sourcing quality material in the first place.'),
      p('b15',
        'Typical shelf life for lyophilized peptides from a USP 797 compliant pharmacy is 6–12 months refrigerated, depending on the specific compound. Reconstituted solutions typically carry beyond-use dates of 28–30 days refrigerated, though this varies. Check the documentation that ships with your compound rather than applying a generic rule.'),
      h2('b16', 'Traveling with Peptides'),
      p('b17',
        'If you need to travel with peptides, keep them refrigerated as long as possible. A small insulated travel case with ice packs can maintain refrigeration temperature for 24–48 hours depending on conditions. TSA regulations allow ice packs when they are still fully frozen at the checkpoint. Declare compounded medications clearly. Carry the original pharmacy packaging with your name, the pharmacy name, and the compound name visible.'),
      p('b18',
        'For international travel, be aware that peptides may be regulated differently in other countries. Research the regulations of your destination before traveling with compounded peptides.'),
      h2('b19', 'The Bottom Line'),
      p('b20',
        'You can compromise the quality of your peptides before they ever reach your body by storing or handling them incorrectly. Refrigerate lyophilized vials, refrigerate reconstituted solutions without freezing them, keep them away from light, use bacteriostatic water for reconstitution, and respect the beyond-use date. The investment in quality USA-compounded peptides is only as good as the storage conditions you maintain once they are in your hands.'),
    ],
  },

  // ── POST 14 ────────────────────────────────────────────────────────────────
  {
    _id: 'post-rfk-restores-12-peptides',
    _type: 'blogPost',
    title: 'RFK Jr. Moves to Restore Access to 12 Peptides — What It Means',
    slug: { _type: 'slug', current: 'rfk-restores-access-12-peptides' },
    author: AUTHOR_REF,
    publishedAt: '2026-04-16T09:00:00Z',
    excerpt:
      'Secretary Kennedy has announced that HHS will move to restore compounding access for 12 peptides previously restricted under the FDA\'s 2023 Category 2 decision. Here is what is actually happening.',
    readingTime: 5,
    featured: true,
    tags: ['FDA', 'regulation', 'BPC-157', 'peptides', 'news'],
    seoTitle: 'RFK Jr. Restores Access to 12 Peptides | Greenstone Peptides',
    seoDescription:
      'Secretary Kennedy announces FDA will review 12 peptides including BPC-157 for regulated access. What this means for peptide therapy.',
    body: [
      p('b1',
        'In recent weeks, Department of Health and Human Services Secretary Robert F. Kennedy Jr. has publicly indicated that HHS intends to move toward restoring compounding access to twelve peptides that were restricted under the FDA&rsquo;s 2023 Category 2 bulk drug substance decision. The announcement has generated significant attention in the peptide therapy community. This article explains the regulatory context, which peptides are involved, what the announcement actually means procedurally, and what it does not mean.'),
      h2('b2', 'The 2023 Category 2 Decision: What It Was'),
      p('b3',
        'In September 2023, the FDA moved several peptides to Category 2 of its bulk drug substances list under the 503A compounding pathway. Category 2 designation means the FDA has determined that there is insufficient clinical data in the human regulatory record to support compounding the substance for routine dispensing. Among the peptides moved to Category 2 were BPC-157, CJC-1295, and several others that had developed significant clinical followings in functional medicine, sports medicine, and longevity practices.'),
      p('b4',
        'The practical effect was that licensed compounding pharmacies could no longer compound these peptides for routine in-office dispensing through the standard 503A pathway. Access through legitimate pharmacy channels was curtailed significantly, and demand shifted — in some cases — toward the unregulated research chemical market that the FDA subsequently targeted in its March 2026 enforcement actions.'),
      h2('b5', 'The Kennedy Announcement'),
      p('b6',
        'Secretary Kennedy&rsquo;s public statements indicate that HHS is pursuing reclassification of twelve peptides, moving them away from Category 2 restriction and toward a regulated compounding access pathway. The peptides identified in public reporting include BPC-157, TB-500, GHK-Cu, and MOTS-c, among others. The policy rationale cited by Kennedy aligns with a broader HHS emphasis on expanding access to compounds with documented clinical use and safety records, while maintaining quality standards.'),
      h2('b7', 'What This Means for BPC-157, TB-500, GHK-Cu, and MOTS-c'),
      p('b8',
        'If the reclassification moves forward through the formal regulatory process, these compounds would be eligible for compounding under standard 503A pathways again. Licensed compounding pharmacies could dispense them with full compliance, batch testing, and the quality infrastructure that the current gray market cannot provide. For patients who have been using these compounds, that would mean access to verified, USA-compounded material through legitimate channels rather than navigating an unregulated market.'),
      p('b9',
        'MOTS-c deserves specific mention as a compound with growing interest in longevity research. It is a mitochondria-derived peptide with preliminary data suggesting metabolic and anti-aging effects. Its inclusion in the proposed reclassification reflects a broadening of the regulatory conversation beyond the most commercially prominent peptides.'),
      h2('b10', 'What This Does Not Mean'),
      p('b11',
        'As of the time of writing, no reclassification has been enacted. Public statements from a cabinet secretary are not regulatory changes. Any reclassification must move through the FDA&rsquo;s formal rulemaking process, which includes public comment periods, agency review, and finalization of new rules. That process takes time — historically, months to years for significant regulatory changes.'),
      p('b12',
        'This means the current regulatory landscape has not changed. Peptides that are currently in Category 2 remain in Category 2. Buyers should not treat a policy announcement as a green light to source from unregulated channels on the assumption that the regulatory environment is about to relax. The enforcement actions against research peptide companies remain in effect. The quality and safety arguments for sourcing from licensed USA compounding pharmacies remain unchanged regardless of future regulatory direction.'),
      h2('b13', 'The Bigger Picture'),
      p('b14',
        'The Kennedy announcement represents the most significant policy signal toward expanded peptide access in several years. It suggests that at the federal level, there is appetite for a regulatory pathway that distinguishes between uncontrolled overseas research peptides and quality-controlled USA-compounded peptides — which is the distinction that has always mattered from a patient safety standpoint.'),
      p('b15',
        'Greenstone Peptides operates within the legitimate compounding pharmacy model now and will continue to operate within it under any future regulatory framework. Our interest is in quality and traceability, not in regulatory gray zones. When and if reclassification creates new compounding pathways for BPC-157, TB-500, and other currently restricted peptides, those pathways will be available through our licensed pharmacy partners with the same testing and documentation standards we apply to everything we currently offer.'),
      h2('b16', 'The Bottom Line'),
      p('b17',
        'RFK Jr.&rsquo;s announcement is a meaningful policy signal, not an enacted change. It suggests regulatory momentum toward expanded compounding access for twelve peptides including BPC-157, TB-500, GHK-Cu, and MOTS-c. Formal reclassification requires a regulatory process that has not yet completed. Until it does, the current rules apply — and the case for sourcing from licensed USA compounding pharmacies with full quality controls remains the only defensible position regardless of where the regulatory landscape moves.'),
    ],
  },

  // ── POST 15 ────────────────────────────────────────────────────────────────
  {
    _id: 'post-tb-500-vs-bpc-157',
    _type: 'blogPost',
    title: 'TB-500 vs BPC-157: Which Recovery Peptide Is Right for You?',
    slug: { _type: 'slug', current: 'tb-500-vs-bpc-157' },
    author: AUTHOR_REF,
    publishedAt: '2026-04-16T10:00:00Z',
    excerpt:
      'TB-500 and BPC-157 are both recovery peptides with documented healing effects, but they work through different mechanisms. Understanding the distinction helps clarify which is appropriate — and when stacking makes sense.',
    readingTime: 7,
    featured: false,
    tags: ['TB-500', 'BPC-157', 'recovery', 'comparison'],
    seoTitle: 'TB-500 vs BPC-157 Comparison | Greenstone Peptides',
    seoDescription:
      'TB-500 and BPC-157 are both recovery peptides but work differently. Compare mechanisms, use cases, and which is right for you.',
    body: [
      p('b1',
        'TB-500 and BPC-157 are regularly mentioned in the same breath. Both are recovery peptides. Both have documented healing effects in animal research. Both are used by athletes, active individuals, and clinicians focused on musculoskeletal repair. But they work through fundamentally different mechanisms, target different tissue processes, and have different evidence profiles. Understanding those differences is the basis for making an informed choice.'),
      h2('b2', 'BPC-157: The Angiogenesis and Tendon Repair Peptide'),
      p('b3',
        'BPC-157 is a fifteen-amino-acid fragment derived from a protein found in human gastric juice. Its primary healing mechanism runs through the VEGFR2/Akt-eNOS axis — it upregulates vascular endothelial growth factor receptor 2, which triggers a signaling cascade that drives angiogenesis: the formation of new blood vessels in injured tissue. Better microvascular supply means better oxygen delivery, improved nutrient delivery, and faster recruitment of the cellular machinery responsible for repair.'),
      p('b4',
        'BPC-157 also upregulates growth hormone receptor expression in tendon fibroblasts and tenocytes, which accelerates tendon and ligament healing specifically. This dual mechanism — angiogenesis plus direct tendon cell stimulation — makes it particularly well-suited for tendon, ligament, and musculotendinous junction injuries. Its gastric origin also makes it one of the few recovery peptides with meaningful evidence for GI tissue repair, including healing of gastric ulcers, NSAID-damaged mucosa, and inflammatory bowel conditions.'),
      h2('b5', 'TB-500: The Systemic Tissue Repair Peptide'),
      p('b6',
        'TB-500 is a synthetic fragment of thymosin beta-4, a protein that plays a central role in actin polymerization — the process by which cells build the structural scaffolding that allows them to migrate, divide, and repair tissue. When TB-500 is administered, it promotes cell migration to sites of injury, reduces local inflammation, and supports angiogenesis through a pathway distinct from BPC-157&rsquo;s VEGFR2 mechanism.'),
      p('b7',
        'The defining characteristic of TB-500 relative to BPC-157 is systemic reach. Thymosin beta-4 is widely distributed in the body, and TB-500&rsquo;s effects are not confined to the injection site or to specific tissue types. Animal research has documented TB-500 effects on cardiac tissue repair, neurological recovery, wound healing, and muscle regeneration. It behaves more like a broad-spectrum tissue repair signal than a targeted tendon-specific intervention.'),
      h2('b8', 'Head-to-Head: Where Each Excels'),
      h3('b9', 'BPC-157 Is Preferred For'),
      p('b10',
        'Tendon and ligament injuries — particularly Achilles, rotator cuff, and knee ligament — represent BPC-157&rsquo;s strongest evidence base. Gastrointestinal repair, including healing from chronic NSAID use or ulceration, is another area where BPC-157&rsquo;s gastric origin gives it a distinct advantage. Local injection near the injury site amplifies its effects by concentrating the angiogenic signal at the repair location.'),
      h3('b11', 'TB-500 Is Preferred For'),
      p('b12',
        'Systemic recovery goals — multiple injury sites, broader tissue repair needs, or situations where systemic administration is preferable to local injection — lean toward TB-500. Its systemic distribution makes it more appropriate when the goal is whole-body recovery rather than a targeted tissue repair. Some clinicians favor TB-500 for cardiac and neurological recovery contexts, though the human evidence base in those areas remains limited.'),
      h2('b13', 'Stacking TB-500 and BPC-157'),
      p('b14',
        'Because the two peptides work through different mechanisms and are not competing for the same receptor pathways, they are commonly used together. The combination provides complementary effects: BPC-157 drives targeted angiogenesis and tendon-specific repair while TB-500 provides broader tissue migration signals and systemic support. Research on the combined stack is limited relative to each compound individually, but the mechanistic rationale for stacking is well-reasoned and the safety profiles of both compounds are consistent with concurrent use.'),
      h2('b15', 'Dosing Considerations'),
      p('b16',
        'BPC-157 is typically used in daily or twice-daily dosing protocols, often injected subcutaneously near the injury site for localized injuries or systemically for GI use. TB-500 is typically dosed on a less frequent schedule — commonly two to four milligrams twice weekly during an initial loading phase, followed by a maintenance frequency that varies by protocol. Dosing for both should be approached with current clinical guidance rather than arbitrary figures from forum posts.'),
      h2('b17', 'Sourcing: The Variable That Overrides Everything Else'),
      p('b18',
        'The comparison between TB-500 and BPC-157 is only meaningful when both compounds are what they claim to be. Independent testing of research-grade peptides purchased online has shown that purity variance is the rule rather than the exception. A vial of BPC-157 at 3% labeled concentration does not produce BPC-157 results — it produces nothing, or worse. The same applies to TB-500.'),
      p('b19',
        'Greenstone Peptides offers both BPC-157 and TB-500 compounded by licensed USA pharmacy partners under full USP 797 standards, with batch-specific Certificates of Analysis confirming potency, sterility, and endotoxin levels. Whether you are using one or both, the foundation is verified material.'),
      h2('b20', 'The Bottom Line'),
      p('b21',
        'BPC-157 and TB-500 are complementary tools, not substitutes. BPC-157 is the more targeted intervention for tendon, ligament, and GI repair. TB-500 is the more systemic tool for broad tissue repair and recovery contexts. Stacking both is mechanistically rational and commonly practiced. The choice depends on the specific injury, the desired scope of effect, and individual response. Both require the same foundation: USA-compounded, verified material from a licensed pharmacy with documented quality controls.'),
    ],
    relatedProductSlug: 'tb-500-5mg',
  },
];

// ─── SEED ─────────────────────────────────────────────────────────────────────

async function seed() {
  console.log('Greenstone Peptides — Blog Post Seeder');
  console.log('─────────────────────────────────────');

  if (!process.env.NEXT_PUBLIC_SANITY_PROJECT_ID) {
    console.error('Missing NEXT_PUBLIC_SANITY_PROJECT_ID in .env.local');
    process.exit(1);
  }
  if (!process.env.SANITY_API_TOKEN) {
    console.error('Missing SANITY_API_TOKEN in .env.local');
    process.exit(1);
  }

  console.log(`\nProject: ${process.env.NEXT_PUBLIC_SANITY_PROJECT_ID}`);
  console.log(`Dataset: ${process.env.NEXT_PUBLIC_SANITY_DATASET || 'production'}`);

  // Author
  console.log('\nSeeding author document...');
  try {
    await client.createOrReplace(author);
    console.log(`  ok  ${author.name}`);
  } catch (err) {
    console.error(`  fail  ${author.name} — ${err.message}`);
    process.exit(1);
  }

  // Posts
  console.log(`\nSeeding ${posts.length} blog posts...`);
  let success = 0;
  let failed = 0;

  for (const post of posts) {
    try {
      // Strip any helper fields that are not part of the schema
      const { relatedProductSlug, ...doc } = post;
      await client.createOrReplace(doc);
      console.log(`  ok  ${post.title}`);
      success++;
    } catch (err) {
      console.error(`  fail  ${post.title} — ${err.message}`);
      failed++;
    }
  }

  console.log('\n─────────────────────────────────────');
  console.log(`Seeded: ${success} / ${posts.length}`);
  if (failed > 0) console.log(`Failed: ${failed}`);
  console.log('Done.');
}

seed().catch((err) => {
  console.error('Fatal seed error:', err);
  process.exit(1);
});
